外周动脉疾病女性他汀使用及强度的性别差异:系统综述
仅2项研究报告高强度他汀的性别差异,均显示女性使用率低于男性;女性接受任何他汀或指南一致性血管保护治疗的可能性普遍低于男性。
要点
- PAD女性高强度他汀使用率低于男性,仅2项研究报告该结局。
- 女性接受任何他汀或指南一致性血管保护治疗的可能性普遍低于男性。
- 纳入研究均未报告LDL-C达标情况的性别差异。
核心结论
- PAD女性接受他汀治疗和指南一致性血管保护治疗的可能性低于男性。
- 有限证据提示当报告他汀强度时,女性高强度他汀使用率低于男性。
- PAD二级预防存在持续的性别差距。
研究设计与样本
- 系统综述,检索PubMed/MEDLINE和Cochrane CENTRAL,从建库至2026年6月6日。
- 主要结局为女性与男性PAD患者高强度他汀使用;因异质性采用叙述性综合。
主要发现
- 仅2项研究报告按性别的高强度他汀使用,均发现女性使用率低于男性。
- 在重症肢体缺血Medicare队列中,女性高强度他汀使用率低于男性。
- 在退伍军人事务队列中,PAD女性高强度他汀使用率、任何他汀使用率和依从性均较低。
- 在初级保健、出院、血运重建、行政索赔和血管登记等场景,女性接受他汀或指南一致性血管保护治疗的可能性普遍低于男性。
- 纳入研究未报告LDL-C达标情况。
临床怎么用
- 临床应关注PAD女性他汀处方不足,尤其高强度他汀的使用。
- 质量改进应聚焦提高PAD女性的他汀处方率。
- 未来研究应按性别报告他汀强度、依从性、LDL-C达标和治疗升级。
局限性
- 纳入研究设计、PAD定义、临床场景和结局报告存在异质性,仅作叙述性综合。
- 仅2项研究报告按性别的高强度他汀使用。
- 纳入研究未报告LDL-C达标情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Peripheral artery disease (PAD) is a manifestation of systemic atherosclerotic cardiovascular disease and is associated with substantial cardiovascular and limb-related morbidity. High-intensity statin therapy is recommended for patients with PAD, yet statin treatment remains underused, and sex-based differences in lipid-lowering therapy may further contribute to inequities in secondary prevention. This systematic review evaluated sex-based disparities in statxin use and statin intensity among adults with PAD. METHODS: A systematic search of PubMed/MEDLINE and Cochrane CENTRAL was performed from database inception through June 6, 2026. Eligible studies included adults with PAD, reported PAD-specific statin or lipid-lowering outcomes, and compared outcomes by sex. The primary outcome was high-intensity statin use among women versus men with PAD. Secondary outcomes included any statin use, no statin therapy, guideline-concordant lipid-lowering or vascular-protective therapy, and low-density lipoprotein cholesterol (LDL-C) goal achievement. Findings were synthesized narratively because of heterogeneity in study design, PAD definition, clinical setting, and outcome reporting. RESULTS: Eleven observational studies met inclusion criteria. Only two studies reported high-intensity statin use by sex, and both found lower use among women than men. In the Medicare cohort of patients with critical limb ischemia, high-intensity statin use was lower among women than men. Similarly, in the Veterans Affairs cohort, women with PAD had lower rates of high-intensity statin use, any statin use, and statin adherence. Across studies reporting secondary lipid-lowering outcomes, women were generally less likely than men to receive statins or guideline-concordant vascular-protective therapy, including in primary care, hospital discharge, revascularization, administrative claims, and vascular registry settings. LDL-C goal achievement was not reported in the included studies. CONCLUSION: Women with PAD are less likely than men to receive statin therapy and guideline-concordant vascular-protective treatment, and the limited available evidence suggests lower use of high-intensity statins among women when statin intensity is reported. These findings highlight a persistent sex-based gap in secondary prevention for PAD. Future studies should report statin intensity, adherence, LDL-C goal achievement, treatment escalation, and standardized measures of statin tolerance or intolerance separately by sex. Quality-improvement efforts should also focus on improving statin prescribing for women with PAD.
引用
- Azeem A, Huynh C. Sex-Based Disparities in Statin Use and Intensity among Women with Peripheral Artery Disease: A Systematic Review. Ann Vasc Surg. 2026. PMID: 42838480. doi:10.1016/j.avsg.2026.09.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。